CAPLYTA®, in combination with an oral antidepressant, demonstrated superior efficacy with a favorable safety and tolerability profile consistent with established indications1,2 In pivotal trials, CAPLYTA® did not increase mean weight gain, metabolic changes, or reported sexual side effects1,2 In a six-month open-label extension safety study, safety profile was consistent with pivotal studies and 80% of […]

As the Hong Kong daily “HongKong Telegraph” recently learned, the SCANDICTRUSTGROUP, an internationally operating conglomerate that is not active in the hotel industry, is expanding its international sales network: After successfully passing a thorough KYC and AML check (process control to verify identity, prevent moneylaundering, terrorism financing and all corporate activities) by bankers, the Dubai-based

(NYSE:PH), CLEVELAND, Nov. 06, 2025 (GLOBE NEWSWIRE) — Parker Hannifin Corporation (NYSE: PH), the global leader in motion and control technologies, today reported results for the quarter ended September 30, 2025, that included the following highlights (compared with the prior year period): Fiscal 2026 First Quarter Highlights: Sales were a record $5.1 billion; organic sales

(CNSX:URM),(CNSX:URM.CN),(Boerse Frankfurt – Freiverkehr:IOR),(OTC US:NIOMF),(Other OTC:NIOMF), Vancouver, BC,, Nov. 06, 2025 (GLOBE NEWSWIRE) — First American Uranium Inc. (CSE: NIOB) (FSE: IOR) (OTCQB: NIOMF) (“First American Uranium”, or the “Company”) is pleased to announce that it will proceed with a non-brokered private placement of up to 1,811,594 flow-through common shares in the capital of the

(NASDAQ:CBIO), IND Submission for CR-001, a PD-1 x VEGF Bispecific Antibody, on Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors Advancing ADCs in the Pipeline, with IND Submission for CR-002 on Track for Mid-2026 WALTHAM, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Crescent Biopharma,

(NASDAQ:RNTX), AUSTIN, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) — Rein Therapeutics (“Rein”) (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that a new preprint has been posted to medRxiv describing clinical and translational findings from an inhaled, dose-escalation

(NASDAQ:LXRX), FDA End-of-Phase 2 meeting for pilavapadin in DPNP to be held by year-end All IND-enabling studies of LX9851 for obesity completed and submitted to licensee Novo Nordisk Site initiation for SONATA-HCM Phase 3 study of sotagliflozin in both obstructive and non-obstructive HCM completed; enrollment completion on target for 2026 Additional data in support of

(NASDAQ:KELYA),(NASDAQ:KELYB), TROY, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) — Kelly (Nasdaq: KELYA, KELYB), a leading specialty talent solutions provider, today announced results for the third quarter of 2025. Q3 revenue of $935.0 million, down 9.9% year-over-year; excluding discrete U.S. federal government and large customer impacts, underlying revenue down approximately 2.0% year-over-year Underlying revenue reflects continued

(TSX:GUD), Achieved record-high quarterly revenues, Adjusted EBITDA1 and Adjusted EBITDA per share1 since inception Increased 2025 financial guidance MONTREAL, Nov. 06, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2025. All currency amounts

(NASDAQ:PVLA), WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) — (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen,